argenx to host workshop and webcast announcing topline clinical TCL data and preclinical AML data from ARGX-110 program

Accessibility: Skip TopNav

December 07, 2015 01:00 ET

Workshop and webcast to occur at 12:00 pm ET today

Breda, the Netherlands / Ghent, Belgium, 7 December 2015 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it will host a workshop and webcast to discuss new ARGX-110 data, in conjunction with the American Society of Hematology (ASH) Annual Meeting. The data on ARGX-110, a novel anti-CD70 therapeutic antibody, include topline clinical results in T-cell lymphoma (TCL) and preclinical data in acute myelogenous leukemia (AML).

The workshop is being held today at 12:00 pm ET and is titled: "CD70 biology targeting TCL and AML." It will showcase promising efficacy of ARGX-110 in TCL patients from phase 1b clinical studies and preclinical data from a collaboration with the Tumor Immunology Lab led by Prof. A. F. Ochsenbein at the University of Bern demonstrating that CD70/CD27 signaling is a novel therapeutic target in acute myeloid leukemia.

The workshop will be webcast and is accessible on the arGEN-X website www.argen-x.com or by clicking here.

ARGX-110 is a SIMPLE Antibody(TM) targeting CD70, an immune checkpoint target involved in hematological malignancies, several solid tumors and severe autoimmune diseases. ARGX-110 works in three ways: i) blocks growth of tumor cells, ii) kills cancer cells and iii) restores immune surveillance against tumors (Silence K. et al. mAbs 2014; 6 (2):523-532). ARGX-110 is currently being evaluated in hematological and solid tumors.

argenx combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey.

argenx is listed on the Euronext Brussels exchange under the symbol ARGX.

SIMPLE Antibody(TM), NHance(TM) and ABDEG(TM) are trademarks of argenx NV

POTELLIGENT® is a trademark of BioWa Inc.

For further information, please contact:

Joke Comijn, Corporate Communications Manager

Mark Swallow/David Dible

Citigate Dewe Rogerson

Beth DelGiacco (US IR)

Stern Investor Relations

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx' actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. "Management's Discussion and Analysis of Financial Condition and Results of Operations"